目的:探讨转录激活因子-2(ATF-2)、切除修复交叉互补基因1(ERCC1)表达在卵巢上皮性癌顺铂化疗耐药中的意义.方法:应用SP法检测56例石蜡包埋卵巢癌标本及RT-PCR方法检测34例卵巢癌新鲜组织ATF-2、ERCC1蛋白及mRNA的表达,分析其与顺铂耐药的关系以及二者的相关性.结果:ATF-2表达与患者年龄、组织学类型及有无腹水无关,不同手术分期其表达差异有统计学意义(P＜0.05).ERCC1表达与卵巢上皮性癌患者年龄、手术分期、病理组织学类型及有无腹水无关(P＞0.05).顺铂化疗耐药组ATF-2、ERCC1蛋白的阳性表达率分别为69.23%、73.08%,高于化疗敏感组33.33%、46.67%,组间差异有统计学意义(P＜0.05).RT-PCR结果显示34例卵巢上皮性癌新鲜组织ATF-2/β-actinmRNA、ERCC1/β-actin分别波动于0.181～2.276、0.294～3.060,化疗耐药者ATF-2 mRNA、ERCC1 mRNA相对表达量分别为1.132±0.645、1.565±0.714,亦高于敏感组0.651±0.461、0.594±0.268,差异有统计学意义(P＜0.05).结论:ATF-2、ERCC1表达与卵巢上皮性癌顺铂耐药有关,可能成为预测卵巢癌顺铂敏感性指标.%Objective: To investigate the significance of the expressions of ATF-2, ERCC1 in cisplatin resistance of ovarian epithelial carcinoma.Methods: The expressions of ATF-2, ERCC1 proteins in 56 ovarian cancer samples were examined by Streptavidin-peroxidase complex technique and the semi-quantitative reverse transcription polymerase chain reaction ( RT-PCR )method were applied to assess the mRNA levels of ATF-2, ERCC1 genes in 34 ovarian carcinoma fresh tissues, the relationships were analyzed between the expressions of ATF-2, ERCC1 and cisplatin resistance.Results: The expressions of ERCC1 did not show any association with patient age,FIGO stage, pathologic type and ascitic fluid, the expressions of ATF-2 were related to FIGO stage.The positive rates of ATF-2, ERCC1 proteins in chemoresistant group were 69.23％, 73.08％ respectively, those of chemosensitive one were 33.33％, 46.67％, with significant difference between the two groups (P＜0.05).The RT-PCR results showed up the range of ATF-2/β-actin mRNA levels were from 0.181 to 2.276, ERCC1/β-actin mRNA levels were from 0.294 to 3.060, the mean of ATF-2 mRNA, ERCC1 mRNA levels in chemoresistant patients were 1.132±0.645, 1.565±0.714 respectively, higher than those of chemosensitive patients 0.651 ±0.461, 0.594±0.268 (P＜0.05).Conclusion: The expressions of ATF-2, ERCC1 were related to cisplatin resistance in ovarian epithelial carcinoma, which may be valuable in predicting cisplatin response.
展开▼
